reclassify Marinol (dronabinol) from Schedule II to Schedule III

The DEA is proposing to reclassify Marinol (dronabinol) from Schedule II to Schedule III.

Marinol has a low potential for abuse. Its slow onset doesn't produce the same high that people get from smoking marijuana.

Reclassifying Marinol might encourage more physicians to prescribe it...and reduce the demand for "medical marijuana."

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote